Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection

InvestorPlace2022-04-07

Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

193

Report

Comment（9）

SlowNana
·2022-04-07
Good analysis but am hoping for a miracle
Reply
4
Report
ThinkOrSwim
·2022-04-07
A sensible article that I can agree upon. Don't buy just b'cos it is low - cos low can go lower, evenwhen technicals seem 'attractive'. [Cool]
Reply
3
Report
moneyfreedom
·2022-04-07
Zhhs
Reply
5
Report
KeN3
·2022-04-07
Losing money on this
Reply
4
Report
逢場作戲又一日
·2022-04-07
Great
Reply
3
Report
Alex1225
·2022-04-07
Like pls
Reply
5
Report
njkk
·2022-04-07
Pls like
Reply
3
Report
Cockatoo
·2022-04-07
🤔
Reply
2
Report
Toby_Chua
·2022-04-07
Vaccine plays are over with winding down of COVID
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1124175646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-07 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124175646","market":"us","top_or_hot":-1,"title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","media":"InvestorPlace","content":"<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","article_id":"1124175646","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","pubTimestamp":1649297545,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"NVAX股票在52周低点是买进吗？跳过Novavax投资组合注入","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9012824654,"gmtCreate":1649307108606,"gmtModify":1676534489653,"author":{"id":"3586490126059662","authorId":"3586490126059662","name":"SlowNana","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3586490126059662","idStr":"3586490126059662"},"htmlText":"Good analysis but am hoping for a miracle&nbsp;","listText":"Good analysis but am hoping for a miracle&nbsp;","text":"Good analysis but am hoping for a miracle","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012824654","repostId":1124175646,"repostType":2,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012862171,"gmtCreate":1649305568923,"gmtModify":1676534489335,"author":{"id":"4107161170881400","authorId":"4107161170881400","name":"ThinkOrSwim","avatar":"https://static.itradeup.com/news/456b9d740a0500cd2e7af1a1332c61de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4107161170881400","idStr":"4107161170881400"},"htmlText":"A sensible article that I can agree upon. Don't buy just b'cos it is low - cos low can go lower, evenwhen technicals seem 'attractive'.&nbsp;[Cool]&nbsp;","listText":"A sensible article that I can agree upon. Don't buy just b'cos it is low - cos low can go lower, evenwhen technicals seem 'attractive'.&nbsp;[Cool]&nbsp;","text":"A sensible article that I can agree upon. Don't buy just b'cos it is low - cos low can go lower, evenwhen technicals seem 'attractive'. [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012862171","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012884248,"gmtCreate":1649304700940,"gmtModify":1676534489147,"author":{"id":"3585016169113806","authorId":"3585016169113806","name":"moneyfreedom","avatar":"https://static.tigerbbs.com/0d3d86db039526e68f0ef11b938e4ed9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3585016169113806","idStr":"3585016169113806"},"htmlText":"Zhhs","listText":"Zhhs","text":"Zhhs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012884248","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012810741,"gmtCreate":1649301857737,"gmtModify":1676534488659,"author":{"id":"4090570965971460","authorId":"4090570965971460","name":"KeN3","avatar":"https://static.tigerbbs.com/ffc770a2d3626a3e029ba2c461aac13d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4090570965971460","idStr":"4090570965971460"},"htmlText":"Losing money on this","listText":"Losing money on this","text":"Losing money on this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012810741","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012832397,"gmtCreate":1649301010769,"gmtModify":1676534488555,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"逢場作戲又一日","avatar":"https://community-static.tradeup.com/news/6a5fbf2ceb7c7ee0399d41e6348dadf7","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3555043402922696","idStr":"3555043402922696"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012832397","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012896890,"gmtCreate":1649299820924,"gmtModify":1676534488298,"author":{"id":"3581747766858829","authorId":"3581747766858829","name":"Alex1225","avatar":"https://static.tigerbbs.com/4a6d122a9e87329fc98cd47b2cd58d8f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3581747766858829","idStr":"3581747766858829"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012896890","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012893836,"gmtCreate":1649299434621,"gmtModify":1676534488226,"author":{"id":"3575950181915531","authorId":"3575950181915531","name":"njkk","avatar":"https://static.tigerbbs.com/6382201e8e84ccd3f8e89b9a28e74607","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575950181915531","idStr":"3575950181915531"},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012893836","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012890693,"gmtCreate":1649299176422,"gmtModify":1676534488221,"author":{"id":"4095668241594670","authorId":"4095668241594670","name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4095668241594670","idStr":"4095668241594670"},"htmlText":"🤔","listText":"🤔","text":"🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012890693","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9012804166,"gmtCreate":1649298894868,"gmtModify":1676534488109,"author":{"id":"3576326749731922","authorId":"3576326749731922","name":"Toby_Chua","avatar":"https://community-static.tradeup.com/news/82ec063fd73ccbceee82eab015cdf3fd","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3576326749731922","idStr":"3576326749731922"},"htmlText":"Vaccine plays are over with winding down of COVID","listText":"Vaccine plays are over with winding down of COVID","text":"Vaccine plays are over with winding down of COVID","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012804166","repostId":1124175646,"repostType":4,"repost":{"id":"1124175646","pubTimestamp":1649297545,"share":"https://ttm.financial/m/news/1124175646?lang=&edition=fundamental","pubTime":"2022-04-07 10:12","market":"us","language":"en","title":"Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1124175646","media":"InvestorPlace","summary":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administrat","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b>NVAX</b>)stock has dropped to a 52-week low amid fears that the <b>Food and Drug Administration</b> will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.</p><p>I find it difficult to comprehend how Novavax will be able to compete with the likes of <b>Pfizer</b>(NYSE:<b>PFE</b>), <b>Johnson &amp; Johnson</b>(NYSE:<b>JNJ</b>), and <b>Moderna</b>(NASDAQ:<b>MRNA</b>). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.</p><p>With higher research &amp; development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.</p><p>Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson &amp; Johnson.</p><p>Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be ...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/04/is-nvax-stock-a-buy-at-52-week-low-skip-the-novavax-portfolio-injection/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124175646","content_text":"Novavax(NASDAQ:NVAX)stock has dropped to a 52-week low amid fears that the Food and Drug Administration will tighten up vaccine distribution policies. A meeting will be held today in which it will be discussed how vaccine makers could articulate their products to circumstances. The FDA is seeking a more proactive solution from vaccine manufacturers that caters to the requirements of specific variants, rather than broad-based protection. According to slides posted ahead of the meeting, there’s a 20% likelihood that an “omicron-like” variant could strike this year, requiring a retooling of vaccine booster shots. A more carefully articulated plan would raise the barriers to entry for vaccine makers and subsequently adjust the risk-return profile of Novavax stock.I find it difficult to comprehend how Novavax will be able to compete with the likes of Pfizer(NYSE:PFE), Johnson & Johnson(NYSE:JNJ), and Moderna(NASDAQ:MRNA). Its protein-based vaccine is effective but holds a less impressive profile than vaccines from the market’s frontrunners.With higher research & development costs to simply keep vaccines up to date with new varients and the FDA concerned about readiness should another omicron variant surge, I can’t see Novavax keeping up with the big guys.Let me contextualize my argument by looking at a few critical data points. The company’s EBITDA margin has decreased by1.46x during the past year, while its cash on hand has also decreased by 26.98% during the same period, suggesting that its spending power is eroding significantly. Furthermore, NVAX’s business model heavily relies on the covid-19 vaccine program as a means of future income. I thus see this as a very risky asset as it doesn’t hold a diversified portfolio of products like Pfizer and Johnson & Johnson.Stock market participants clearly haven’t shown much interest in NVAX stock lately as its trading below its10-, 50-, 100-, and 200-day moving averages. Momentum patterns require a catalyst to reverse, and I just don’t see that happening for Novavax anytime soon.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":193,"commentSize":9,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}